159 related articles for article (PubMed ID: 32715940)
1. Homology modeling and
Elmezayen AD; Yelekçi K
J Biomol Struct Dyn; 2021 Oct; 39(17):6396-6414. PubMed ID: 32715940
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel isoform-selective histone deacetylases 5 and 9 inhibitors through combined ligand-based pharmacophore modeling, molecular mocking, and molecular dynamics simulations for cancer treatment.
Elmezayen AD; Al-Obaidi A; Yelekçi K
J Mol Graph Model; 2021 Jul; 106():107937. PubMed ID: 34049193
[TBL] [Abstract][Full Text] [Related]
3. Homology modeling of human histone deacetylase 10 and design of potential selective inhibitors.
Ibrahim Uba A; Yelekçi K
J Biomol Struct Dyn; 2019 Sep; 37(14):3627-3636. PubMed ID: 30204052
[TBL] [Abstract][Full Text] [Related]
4. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.
Milde T; Oehme I; Korshunov A; Kopp-Schneider A; Remke M; Northcott P; Deubzer HE; Lodrini M; Taylor MD; von Deimling A; Pfister S; Witt O
Clin Cancer Res; 2010 Jun; 16(12):3240-52. PubMed ID: 20413433
[TBL] [Abstract][Full Text] [Related]
5. Hydroxamic acid derivatives as selective HDAC3 inhibitors: computer-aided drug design strategies.
Patel P; Shrivastava SK; Sharma P; Kurmi BD; Shirbhate E; Rajak H
J Biomol Struct Dyn; 2024; 42(1):362-383. PubMed ID: 36995068
[TBL] [Abstract][Full Text] [Related]
6. Specific control of pancreatic endocrine β- and δ-cell mass by class IIa histone deacetylases HDAC4, HDAC5, and HDAC9.
Lenoir O; Flosseau K; Ma FX; Blondeau B; Mai A; Bassel-Duby R; Ravassard P; Olson EN; Haumaitre C; Scharfmann R
Diabetes; 2011 Nov; 60(11):2861-71. PubMed ID: 21953612
[TBL] [Abstract][Full Text] [Related]
7. Crystallographic structure versus homology model: a case study of molecular dynamics simulation of human and zebrafish histone deacetylase 10.
Uba AI; Yelekçi K
J Biomol Struct Dyn; 2020 Sep; 38(15):4397-4406. PubMed ID: 31701819
[TBL] [Abstract][Full Text] [Related]
8. HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression.
Hu T; Schreiter FC; Bagchi RA; Tatman PD; Hannink M; McKinsey TA
J Biol Chem; 2019 May; 294(21):8640-8652. PubMed ID: 30962285
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
El-Awady R; Saleh E; Hamoudi R; Ramadan WS; Mazitschek R; Nael MA; Elokely KM; Abou-Gharbia M; Childers WE; Srinivasulu V; Aloum L; Menon V; Al-Tel TH
Bioorg Med Chem; 2021 Jul; 42():116251. PubMed ID: 34116381
[TBL] [Abstract][Full Text] [Related]
10. Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatorial approach and QM/MM calculations.
Kollar J; Frecer V
J Mol Graph Model; 2018 Oct; 85():97-110. PubMed ID: 30145395
[TBL] [Abstract][Full Text] [Related]
11. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
12. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing.
Liu J; Zhu Y; He Y; Zhu H; Gao Y; Li Z; Zhu J; Sun X; Fang F; Wen H; Li W
J Biomol Struct Dyn; 2020 Feb; 38(2):533-547. PubMed ID: 30938574
[TBL] [Abstract][Full Text] [Related]
13. HDAC4 and HDAC5 form a complex with DREAM that epigenetically down-regulates NCX3 gene and its pharmacological inhibition reduces neuronal stroke damage.
Formisano L; Laudati G; Guida N; Mascolo L; Serani A; Cuomo O; Cantile M; Boscia F; Molinaro P; Anzilotti S; Pizzorusso V; Di Renzo G; Pignataro G; Annunziato L
J Cereb Blood Flow Metab; 2020 Oct; 40(10):2081-2097. PubMed ID: 31696766
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
Uba AI; Yelekçi K
J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
[TBL] [Abstract][Full Text] [Related]
15. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
16. Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling.
Mazzocchi M; Wyatt SL; Mercatelli D; Morari M; Morales-Prieto N; Collins LM; Sullivan AM; O'Keeffe GW
Front Cell Dev Biol; 2019; 7():191. PubMed ID: 31572723
[TBL] [Abstract][Full Text] [Related]
17. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
18. HDAC9 as a Privileged Target: Reviewing its Role in Different Diseases and Structure-activity Relationships (SARs) of its Inhibitors.
Das T; Khatun S; Jha T; Gayen S
Mini Rev Med Chem; 2024; 24(7):767-784. PubMed ID: 37818566
[TBL] [Abstract][Full Text] [Related]
19. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
Kashyap K; Kakkar R
J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
[TBL] [Abstract][Full Text] [Related]
20. In silico structure prediction and inhibition mechanism studies of AtHDA14 as revealed by homology modeling, docking, molecular dynamics simulation.
Zhao ML; Wang W; Nie H; Cao SS; Du LF
Comput Biol Chem; 2018 Aug; 75():120-130. PubMed ID: 29775968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
